Alkermes (ALKS) Projected to Post Earnings on Thursday

Key Points

• Alkermes is expected to report its Q3 2025 earnings on Thursday, October 23rd, with analysts predicting earnings of $0.41 per share and revenue of $355.23 million.
• As of now, Alkermes shares are rated as a Moderate Buy by analysts, with a consensus target price of $42.00.
• Insider activity includes the sale of 9,000 shares by EVP Craig C. Hopkinson, decreasing his position by 10.88%.

Alkermes (NASDAQ:ALKS - Get Free Report) will likely be issuing its Q3 2025 results before the market opens on Thursday, October 23rd. Analysts expect the company to announce earnings of $0.41 per share and revenue of $355.23 million for the quarter. Alkermes has set its FY 2025 guidance at 1.030-1.210 EPS.Parties can find conference call details on the company's upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Thursday, October 23, 2025 at 8:00 AM ET.

Alkermes (NASDAQ:ALKS - Get Free Report) last posted its earnings results on Tuesday, July 29th. The company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.42 by $0.10. Alkermes had a return on equity of 24.86% and a net margin of 23.15%.The firm had revenue of $390.66 million for the quarter, compared to analysts' expectations of $343.20 million. During the same period in the previous year, the firm earned $1.16 earnings per share. The business's revenue was down 2.1% compared to the same quarter last year. On average, analysts expect Alkermes to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Alkermes Stock Up 0.9%

Shares of ALKS stock opened at $32.23 on Thursday. The stock has a fifty day moving average of $28.98 and a 200 day moving average of $29.16. Alkermes has a 52 week low of $25.17 and a 52 week high of $36.45. The firm has a market capitalization of $5.32 billion, a price-to-earnings ratio of 15.50, a PEG ratio of 1.72 and a beta of 0.54.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. The Goldman Sachs Group assumed coverage on shares of Alkermes in a research report on Tuesday, July 15th. They issued a "buy" rating and a $43.00 target price for the company. Needham & Company LLC set a $43.00 price target on shares of Alkermes in a research note on Tuesday, September 9th. Royal Bank Of Canada raised Alkermes from a "sector perform" rating to an "outperform" rating and lifted their price objective for the company from $42.00 to $44.00 in a research report on Friday, September 26th. Wells Fargo & Company upgraded Alkermes to a "strong-buy" rating in a report on Wednesday, September 3rd. Finally, JPMorgan Chase & Co. lifted their price target on Alkermes from $34.00 to $35.00 and gave the company a "neutral" rating in a research report on Tuesday, September 9th. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $42.00.

Insider Activity at Alkermes

In other news, EVP Craig C. Hopkinson sold 9,000 shares of the business's stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $31.53, for a total value of $283,770.00. Following the sale, the executive vice president directly owned 73,740 shares of the company's stock, valued at $2,325,022.20. The trade was a 10.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 4.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Alkermes

Hedge funds have recently added to or reduced their stakes in the stock. Royal Bank of Canada increased its holdings in shares of Alkermes by 117.2% during the first quarter. Royal Bank of Canada now owns 275,526 shares of the company's stock valued at $9,098,000 after acquiring an additional 148,696 shares in the last quarter. Ashton Thomas Private Wealth LLC purchased a new stake in Alkermes during the 1st quarter valued at about $213,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Alkermes by 4.3% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 482,332 shares of the company's stock valued at $15,927,000 after purchasing an additional 20,091 shares in the last quarter. Cetera Investment Advisers increased its stake in Alkermes by 32.3% during the 2nd quarter. Cetera Investment Advisers now owns 13,907 shares of the company's stock valued at $398,000 after purchasing an additional 3,394 shares in the last quarter. Finally, Quantbot Technologies LP raised its holdings in Alkermes by 539.4% in the second quarter. Quantbot Technologies LP now owns 6,976 shares of the company's stock worth $200,000 after buying an additional 5,885 shares during the last quarter. 95.21% of the stock is owned by institutional investors.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.